Canopy Growth stock tumbles after announcing $200 million share sale plan
Teladoc Health, Inc. (NYSE:TDOC), a telehealth company with a market capitalization of $1.47 billion, saw a notable transaction involving its President, International, Carlos Nueno. According to a recent SEC filing, Nueno sold 8,266 shares of common stock on March 20, 2025, at an average price of $8.424 per share. This transaction amounted to a total value of $69,632. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with a "GOOD" overall financial health score.
Before the sale, Nueno acquired 18,225 shares of common stock on March 19, 2025, through the conversion of restricted stock units. These units converted on a one-for-one basis into common stock, as noted in the filing. The transaction comes as Teladoc prepares to report its next earnings on April 23, 2025.
The sale was executed to cover tax withholding obligations related to the vesting of Nueno’s restricted stock unit awards. Following these transactions, Nueno holds 12,891 shares of Teladoc common stock. The company’s shares have declined 46.5% over the past year, though InvestingPro data reveals several additional insights and tips available to subscribers, including detailed analysis in the comprehensive Pro Research Report covering this and 1,400+ other top US stocks.
In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings, showing a revenue of $640.5 million, slightly above the forecast of $638.5 million, though its earnings per share (EPS) of -0.28 missed the expected -0.23. For the full year 2024, Teladoc’s revenue was $2.6 billion, a 1% decrease from the previous year. The company ended the year with $1.3 billion in cash and cash equivalents. Meanwhile, Teladoc has formed a partnership with Gifthealth, a pharmacy partner for Eli Lilly (NYSE:LLY)’s LillyDirect program, to improve access to Zepbound (tirzepatide) for members of its Comprehensive Weight Care Program. This collaboration aims to provide a more streamlined and affordable option for Teladoc Health members who lack insurance coverage for GLP-1s for obesity. Analyst firms such as Truist and Stifel have maintained their Hold ratings on Teladoc shares, with price targets of $10 and $9 respectively, reflecting a cautious outlook following the company’s mixed financial results and strategic partnerships. Additionally, Needham also reiterated a Hold rating after Teladoc’s mixed fourth-quarter results, citing uncertainties regarding the company’s future performance. These developments highlight Teladoc’s ongoing efforts to expand its service offerings while navigating financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.